Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise in controlling advanced GIST tumors

NCT ID NCT00756509

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This phase 4 trial tested the drug nilotinib in 34 adults with advanced GIST that could not be removed by surgery. The goal was to see how many patients had their tumors shrink or stay stable after 6 months. Researchers measured response using standard tumor scans. The study provides early evidence on whether nilotinib could be a useful first treatment for this rare cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nilotinib
What this could lead to
If successful, nilotinib could offer a new first-line treatment option for people with advanced GIST, helping control tumor growth.
What could go wrong
This is a small, single-arm study with only 34 participants, so results may not apply broadly. Nilotinib also has known side effects like heart rhythm changes and liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastrointestinal stromal tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROINTESTINAL STROMAL TUMORS

Contacts and locations

Locations

  • Novartis Investigative Site

    Helsinki, FIN-00029, Finland

  • Novartis Investigative Site

    Lyon, 69373, France

  • Novartis Investigative Site

    Munich, Bavaria, 81377, Germany

  • Novartis Investigative Site

    Bad Saarow, 15526, Germany

  • Novartis Investigative Site

    Essen, 45147, Germany

  • Novartis Investigative Site

    Hanover, 30625, Germany

  • Novartis Investigative Site

    Milan, MI, 20133, Italy

  • Novartis Investigative Site

    Palma, Balearic Islands, 07120, Spain

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

  • Novartis Investigative Site

    Valencia, Valencia, 46009, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.